Immunologic Factor – Page 45

Revolutionizing Public Health: CBER’s Peter Marks and the Vision to Reduce FDA Visits

12 months ago talkbio0Tagged Biological Factors, CBER, healthcare innovation, Measures, Medical Devices, Peter Marks, Prophylactic behavior, public health medicine (field), Regulatory Affairs, United States Food and Drug Administration, Vaccines

CBER, Peter Marks, FDA, public health, healthcare innovation, regulatory affairs, biologics, vaccines, medical devices, preventive measures.

Europe Temporarily Halts AstraZeneca’s Vaxzevria COVID-19 Vaccine on Company’s Request

12 months ago talkbio0Tagged AstraZeneca, authorization, concerns, COVID19 (disease), Europe, European Medicines Agency, Pharmacovigilance, Safety, Suspensions, Vaccines, Vaxzevria

AstraZeneca, Vaxzevria, COVID-19 vaccine, marketing authorization, suspension, Europe, European Medicines Agency (EMA), pharmacovigilance, safety concerns.

FDA to Review Lilly’s Alzheimer’s Drug Donanemab in June Advisory Committee Meeting

12 months ago talkbio0Tagged AdCom, Alzheimer 's, Approved, Donanemab, Eli Lilly, Neurodegenerative Disorders, United States Food and Drug Administration

FDA, Lilly, Alzheimer’s, donanemab, June, AdCom, review, approval, treatment, neurodegenerative disease.

Zenas Biotech Secures $200 Million for Advancing Obexelimab in Pivotal Immunology Trials

12 months ago talkbio0Tagged Autoimmune Diseases, B-cell-directed therapy, Biotechnology, Drug Development, Immunology, Obexelimab, trials, Zenas Biotech

Zenas Biotech, obexelimab, immunology trials, funding, biotechnology, drug development, autoimmune diseases, B-cell-directed therapy.

ADC Therapeutics Showcases Promising Zynlonta Data in Marginal Zone Lymphoma and Secures $105M in Funding

12 months ago talkbio0Tagged Antibody-Drug Conjugates, Biotechnology, Cancer Therapeutic Procedure, Clinical Trials, Health care facility, Mucosa-Associated Lymphoid Tissue Lymphoma, Sales - occupational activity, therapeutic autologous dendritic cells, Zynlonta

ADC Therapeutics, Zynlonta, marginal zone lymphoma, share sale, funding, cancer treatment, antibody-drug conjugate, clinical trials, biotechnology, healthcare.